Position in VCEL
as of Mar 31, 2026
· filed Apr 30, 2026
Position Value
$3,867,992
+$1,268,791 QoQ
Shares Held
120,236
+66.6% QoQ
Ownership
0.235%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Granite Investment Partners, LLC holds $55,186,477 across 10 Biotechnology names. VCEL ranks #6 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
80,299 | $13,572,136 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
54,155 | $10,812,045 | |
| 3 | APLS |
Apellis Pharmaceuticals, Inc.
|
231,917 | $9,330,020 | |
| 4 | TECH |
BIO-TECHNE Corp
|
137,562 | $7,188,990 | |
| 5 | KRYS |
Krystal Biotech, Inc.
|
24,284 | $6,273,042 | |
| 6 | VCEL |
Vericel Corp
This page
|
120,236 | $3,867,992 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
51,719 | $3,342,598 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
5,345 | $401,356 |
All Filings in VCEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,867,992 | 120,236 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $2,599,201 | 72,180 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||